Swissmedic reviewing licence extension for the SGLT2 inhibitor Invokana (canagliflozin) in fast-track procedure

9 October 2019 - The CREDENCE renal outcomes study, which was stopped early in July 2018 owing to positive efficacy findings, ...

Read more →

Swissmedic updates requirements concerning the fast-track authorisation procedure

16 October 2017 - On 1 October 2017, the Swiss Agency for therapeutic products updated its guidance document concerning the ...

Read more →